SOST and osteoporosis: The identification of molecular pathways in osteoporosis has important implications not only for the recognition of individuals in risk, aiming for a personalized medical approach, but also for the development of new therapeutic strategies, as exemplified by the advent of sclerostin inhibition as a potential treatment for osteoporosis roughly ten years after the identification of SOST defects (21).